Breast cancer chemotherapy-related cognitive dysfunction
- PMID: 12533268
- DOI: 10.3816/cbc.2002.s.018
Breast cancer chemotherapy-related cognitive dysfunction
Abstract
Cognitive side effects of systemic chemotherapy have become an increasing concern among breast cancer survivors, their families, and health care professionals. A growing body of research supports the hypothesis that chemotherapy can produce long-term cognitive changes in at least a subgroup of cancer survivors. We review evidence implicating systemic chemotherapy as the cause of cognitive changes; describe the limitations due to lack of longitudinal studies and gaps in knowledge (ie, no clear mechanism by which chemotherapy can produce cognitive changes has been proposed); discuss possible factors like age, intelligence quotient/education, and psychological, genetic, and hormonal factors that might increase risk for chemotherapy-induced cognitive changes; and outline future directions for research. Such future research includes large-scale, longitudinal studies of pretreatment neuropsychological assessments, use of imaging techniques and the development of animal models to study the mechanisms of chemotherapy-induced changes in cognitive functioning, and the development of interventions to prevent or reduce the negative cognitive effects of chemotherapy
Similar articles
-
Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective.Clin Breast Cancer. 2002 Dec;3 Suppl 3:S100-8. doi: 10.3816/cbc.2002.s.020. Clin Breast Cancer. 2002. PMID: 12533270 Review.
-
Assessing cognitive dysfunction in breast cancer: what are the tools?Clin Breast Cancer. 2002 Dec;3 Suppl 3:S91-9. doi: 10.3816/cbc.2002.s.019. Clin Breast Cancer. 2002. PMID: 12533269
-
Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy.Clin Breast Cancer. 2002 Dec;3 Suppl 3:S116-20. doi: 10.3816/cbc.2002.s.022. Clin Breast Cancer. 2002. PMID: 12533272 Review.
-
Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible.Clin Breast Cancer. 2002 Dec;3 Suppl 3:S121-7. doi: 10.3816/cbc.2002.s.023. Clin Breast Cancer. 2002. PMID: 12533273 Review.
-
The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.Cancer. 2004 Jun 1;100(11):2292-9. doi: 10.1002/cncr.20272. Cancer. 2004. PMID: 15160331 Clinical Trial.
Cited by
-
Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures.Neuroimage Clin. 2017 Dec 28;18:86-96. doi: 10.1016/j.nicl.2017.12.032. eCollection 2018. Neuroimage Clin. 2017. PMID: 29387526 Free PMC article.
-
Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research.Support Care Cancer. 2012 Apr;20(4):831-9. doi: 10.1007/s00520-011-1158-0. Epub 2011 May 1. Support Care Cancer. 2012. PMID: 21533812 Free PMC article. Clinical Trial.
-
Mammary tumor and mastectomy synergistically promote neuroinflammation in a breast cancer survivor model.Brain Res. 2019 Mar 15;1707:133-140. doi: 10.1016/j.brainres.2018.11.037. Epub 2018 Nov 26. Brain Res. 2019. PMID: 30496733 Free PMC article.
-
Memory loss during lenalidomide treatment: a report on two cases.BMC Pharmacol Toxicol. 2013 Aug 12;14:41. doi: 10.1186/2050-6511-14-41. BMC Pharmacol Toxicol. 2013. PMID: 23937917 Free PMC article.
-
Relationship between self-reported and objectively measured physical activity and subjective memory impairment in breast cancer survivors: role of self-efficacy, fatigue and distress.Psychooncology. 2017 Sep;26(9):1390-1399. doi: 10.1002/pon.4156. Epub 2016 Jul 8. Psychooncology. 2017. PMID: 27388973 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical